Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

4/8/2025

Janusmed kön och genus

Janusmed kön och genus – Eplerenon

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Eplerenon Testmiljö

Eplerenon

Klass : A

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

Eplerenon Accord, Eplerenon Actavis, Eplerenon Bluefish, Eplerenon Krk......

Eplerenon Accord, Eplerenon Actavis, Eplerenon Bluefish, Eplerenon Krka, Eplerenon Medical Valley, Eplerenon STADA, Eplerenone Sandoz, Eplerenone Teva, Inspra
ATC-koder

C03DA04

C03DA04
Substanser

eplerenon

eplerenon
Sammanfattning

Eplerenon som tilläggsbehandling vid allvarlig hjärtsvikt minskar mortalitet och sjukhusinläggning på ett likvärdigt sätt hos kvinnor och män.

Eplerenon har färre hormonella biverkningar än spironolakton, men dessa kan förekomma vid långtidsbehandling.

Eplerenon som tilläggsbehandling vid allvarlig hjärtsvikt minskar mortalitet och sjukhusinläggning på ett likvärdigt sätt hos kvinnor och män. Eplerenon har färre hormonella biverkningar än spironolakton, men dessa kan förekomma vid långtidsbehandling.
Background

Pharmacokinetics and dosing
Following administration of single or multiple doses of eplerenone (12.5-100 mg) , no differences in pharmacokinetics parameters were found between men and women [1-4]. Black participants had 19% lower Cmax and 26% lower AUC than White participants at steady state [3, 4].

No sex differences in blood pressure reduction, regardless of dose regimens, have been found, and no sex differentiation in dosing is recommended [3].

Effects
In the major clinical trial of eplerenone in patients with acute myocardial infarction and left ventricular dysfunction, the EPHESUS trial (4714 men, 1918 women), mortality hazard ratios were similar for both sexes [5, 6].

The effects of eplerenone on clinical outcomes in patients with systolic heart failure and mild symptoms were investigated in the EMPHASIS-HF trial (2127 men, 610 women). Hazard ratios for hospitalization for heart failure or death from cardiovascular causes with eplerenone versus placebo were similar for men and women [7].

Adverse effects
Eplerenone is more specific than spironolactone in the effect on t......

Visa hela bakgrundstexten

# Pharmacokinetics and dosing Following administration of single or multiple doses of eplerenone (12.5-100 mg) , no differences in pharmacokinetics parameters were found between men and women [1-4]. Black participants had 19% lower Cmax and 26% lower AUC than White participants at steady state [3, 4]. No sex differences in blood pressure reduction, regardless of dose regimens, have been found, and no sex differentiation in dosing is recommended [3]. # Effects In the major clinical trial of eplerenone in patients with acute myocardial infarction and left ventricular dysfunction, the EPHESUS trial (4714 men, 1918 women), mortality hazard ratios were similar for both sexes [5, 6]. The effects of eplerenone on clinical outcomes in patients with systolic heart failure and mild symptoms were investigated in the EMPHASIS-HF trial (2127 men, 610 women). Hazard ratios for hospitalization for heart failure or death from cardiovascular causes with eplerenone versus placebo were similar for men and women [7]. # Adverse effects Eplerenone is more specific than spironolactone in the effect on the mineralocorticoid receptor with minimal effects at other steroid receptors, thereby minimizing many of the hormonal adverse effects [6]. However, sex hormone-related adverse events that have been seen with eplerenone in clinical trials of hypertension. These are gynecomastia in men and abnormal vaginal bleeding in women. These adverse events increased marginally with longer duration of therapy [8]. In the EPHESUS trial mentioned above, adverse events occurred at a similar rate in both sexes [3, 5]. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler män än kvinnor hämtade ut tabletter innehållande eplerenon (ATC-kod C03DA04) på recept i Sverige år 2015, totalt 5 412 män och 1 037 kvinnor. Det motsvarar 1,1 respektive 0,2 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 75-84 år hos båda könen. I genomsnitt var tabletter innehållande eplerenon 5,7 gånger vanligare hos män [7].
Referenser

Visa referenser

  1. Croom KF, Perry CM. Eplerenone: a review of its use in essential hypertension. Am J Cardiovasc Drugs. 2005;5:51-69.

  2. Tolbert DS, Reid SE, Roniker B. Pharmacokinetics of eplerenone in special populations [abstract no 46]. Pharmacotherapy. 2002;22(1):1332.

  3. Inspra (eplerenone). DailyMed [www]. US National Library of Medicine. [updated 2018-06-20, cited 2019-03-04].

  4. Inspra (eplerenon). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2017-03-24, cited 2019-03-04].

  5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.

  6. Seeland U, Regitz-Zagrosek V. Sex and gender differences in cardiovascular drug therapy. Handb Exp Pharmacol. 2012;214:211-36.

  7. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.

  8. Moore TD, Nawarskas JJ, Anderson JR. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 2003;5:354-63.

  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]

  1. Croom KF, Perry CM. Eplerenone: a review of its use in essential hypertension. Am J Cardiovasc Drugs. 2005;5:51-69.
  2. Tolbert DS, Reid SE, Roniker B. Pharmacokinetics of eplerenone in special populations [abstract no 46]. Pharmacotherapy. 2002;22(1):1332.
  3. Inspra (eplerenone). DailyMed [www]. US National Library of Medicine. [updated 2018-06-20, cited 2019-03-04].
  4. Inspra (eplerenon). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2017-03-24, cited 2019-03-04].
  5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.
  6. Seeland U, Regitz-Zagrosek V. Sex and gender differences in cardiovascular drug therapy. Handb Exp Pharmacol. 2012;214:211-36.
  7. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
  8. Moore TD, Nawarskas JJ, Anderson JR. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 2003;5:354-63.
  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]
Uppdaterat

Litteratursökningsdatum: 3/4/2019

Litteratursökningsdatum: 3/4/2019
Fasstexter

Visa fasstexter

Se även

Spironolakton